<p>Spruce Biosciences（纳斯达克代码：SPRB - 获取免费报告）在周三发布给投资者的报告中，被 Leerink Partners 从 “持有” 评级上调至 “强烈买入” 评级，Zacks.com 报道。</p>
<p>其他一些分析师最近也对 SPRB 发布了报告。花旗集团在 11 月 11 日（星期二）的一份研究报告中重申了 Spruce Biosciences 的 “市场表现” 评级。华尔街 Zen 在 11 月 15 日（星期六）的一份研究报告中将 Spruce Biosciences 的评级上调至 “卖出”。Weiss Ratings 在周一的报告中重新发布了 Spruce Biosciences 的 “卖出（e+）” 评级。Leerink Partners 在周三的报告中将 Spruce Biosciences 的评级从 “市场表现” 上调至 “跑赢市场”，并设定了 160.00 美元的目标价。最后，Citizens Jmp 在 11 月 11 日（星期二）的研究报告中将 Spruce Biosciences 的目标价从 254.00 美元提高至 259.00 美元，并给予该股票 “市场跑赢” 的评级。一位分析师给予该股票 “强烈买入” 评级，三位给予 “买入” 评级，六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat，该股票的共识评级为 “持有”，共识目标价为 178.88 美元。</p>
<p>获取 <strong>Spruce Biosciences</strong> 警报：</p>
<p><strong>获取我们最新的 SPRB 股票分析</strong></p>
<h2>Spruce Biosciences 上涨 1.1%</h2>
<p>纳斯达克 SPRB 在周三开盘价为 90.16 美元。该公司的市值为 9647 万美元，市盈率为-1.06，贝塔值为 3.45。该公司的 50 日移动平均价格为 108.33 美元，200 日移动平均价格为 42.17 美元。Spruce Biosciences 的 1 年最低价为 4.28 美元，1 年最高价为 240.00 美元。</p>
<p>Spruce Biosciences（纳斯达克代码：SPRB - 获取免费报告）最近在 11 月 10 日（星期一）发布了其财报。该公司报告本季度每股收益为（14.58 美元），超过了共识预期的（15.56 美元）0.98 美元。研究分析师平均预计 Spruce Biosciences 在当前财政年度将发布-1 美元的每股收益。</p>
<h2>对 Spruce Biosciences 的对冲基金看法</h2>
<p>一家机构投资者最近在 Spruce Biosciences 股票中购买了新头寸。根据该公司在最近向证券交易委员会提交的文件，凯雷集团在第三季度购买了 Spruce Biosciences, Inc.（纳斯达克代码：SPRB - 免费报告）的新头寸。该公司购买了 2,896,518 股该公司的股票，价值约为 24,765,000 美元。Spruce Biosciences 占凯雷集团投资组合的 0.6%，是其第四大头寸。截至最近向证券交易委员会提交的文件，凯雷集团持有 Spruce Biosciences 约 579.30% 的股份。对冲基金和其他机构投资者持有该公司 91.71% 的股票。</p>
<h2>Spruce Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Spruce Biosciences, Inc.是一家生物制药公司，专注于开发和商业化稀有内分泌疾病的新疗法。该公司正在开发 tildacerfont，这是一种非类固醇疗法，旨在增强疾病控制并减少患有先天性肾上腺增生（CAH）患者的类固醇负担，目前处于 2b 期临床试验；并评估在经典 CAH 成人患者中减少糖皮质激素的使用，目前也处于 2b 期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Spruce Biosciences 更好</li>
<li>什么是国债？</li>
<li>MongoDB 刚刚发布了一个爆炸性的季度——但它是否过热？</li>
<li>什么是成长股及其投资</li>
<li>3 只股票有望受益于谷歌的 AI 突破</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>超越 NVIDIA：5 只半导体股票将主导 2026 年</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSQg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Spruce Biosciences 吗？</h2>
<p>在你考虑 Spruce Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Spruce Biosciences 并不在名单上。</p>
<p>虽然 Spruce Biosciences 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SPRB

<p>Leerink Partners 将 Spruce Biosciences（NASDAQ:SPRB）的评级从 “持有” 上调至 “强力买入”。其他分析师的评级则各有不同，普遍维持 “持有” 评级，目标价为 178.88 美元。该股票开盘价为 90.16 美元，市值为 9647 万美元。凯雷集团最近收购了该公司的重要股份。Spruce Biosciences 专注于罕见内分泌疾病的治疗，其主要产品正在进行 2b 期临床试验</p>

<p>Spruce Biosciences (NASDAQ:SPRB - Get Free Report) was upgraded by Leerink Partnrs from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a note issued to investors on Wednesday,Zacks.com reports.</p>
<div class="lb-trans"><p>Spruce Biosciences（纳斯达克代码：SPRB - 获取免费报告）在周三发布给投资者的报告中，被 Leerink Partners 从 “持有” 评级上调至 “强烈买入” 评级，Zacks.com 报道。</p>
</div><p>A number of other analysts have also recently issued reports on SPRB. Citigroup restated a &#34;market perform&#34; rating on shares of Spruce Biosciences in a research note on Tuesday, November 11th. Wall Street Zen upgraded Spruce Biosciences to a &#34;sell&#34; rating in a research note on Saturday, November 15th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Spruce Biosciences in a report on Monday. Leerink Partners raised Spruce Biosciences from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $160.00 price objective on the stock in a report on Wednesday. Finally, Citizens Jmp increased their price objective on Spruce Biosciences from $254.00 to $259.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $178.88.</p>
<div class="lb-trans"><p>其他一些分析师最近也对 SPRB 发布了报告。花旗集团在 11 月 11 日（星期二）的一份研究报告中重申了 Spruce Biosciences 的 “市场表现” 评级。华尔街 Zen 在 11 月 15 日（星期六）的一份研究报告中将 Spruce Biosciences 的评级上调至 “卖出”。Weiss Ratings 在周一的报告中重新发布了 Spruce Biosciences 的 “卖出（e+）” 评级。Leerink Partners 在周三的报告中将 Spruce Biosciences 的评级从 “市场表现” 上调至 “跑赢市场”，并设定了 160.00 美元的目标价。最后，Citizens Jmp 在 11 月 11 日（星期二）的研究报告中将 Spruce Biosciences 的目标价从 254.00 美元提高至 259.00 美元，并给予该股票 “市场跑赢” 的评级。一位分析师给予该股票 “强烈买入” 评级，三位给予 “买入” 评级，六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat，该股票的共识评级为 “持有”，共识目标价为 178.88 美元。</p>
</div><p>Get <strong>Spruce Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spruce Biosciences</strong> 警报：</p>
</div><p><strong>Get Our Latest Stock Analysis on SPRB</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 SPRB 股票分析</strong></p>
</div><h2>Spruce Biosciences Trading Up 1.1%</h2>
<div class="lb-trans"><h2>Spruce Biosciences 上涨 1.1%</h2>
</div><p>NASDAQ SPRB opened at $90.16 on Wednesday. The firm has a market capitalization of $96.47 million, a P/E ratio of -1.06 and a beta of 3.45. The firm's fifty day moving average price is $108.33 and its two-hundred day moving average price is $42.17. Spruce Biosciences has a 1 year low of $4.28 and a 1 year high of $240.00.</p>
<div class="lb-trans"><p>纳斯达克 SPRB 在周三开盘价为 90.16 美元。该公司的市值为 9647 万美元，市盈率为-1.06，贝塔值为 3.45。该公司的 50 日移动平均价格为 108.33 美元，200 日移动平均价格为 42.17 美元。Spruce Biosciences 的 1 年最低价为 4.28 美元，1 年最高价为 240.00 美元。</p>
</div><p>Spruce Biosciences (NASDAQ:SPRB - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($14.58) EPS for the quarter, topping the consensus estimate of ($15.56) by $0.98. On average, research analysts anticipate that Spruce Biosciences will post -1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Spruce Biosciences（纳斯达克代码：SPRB - 获取免费报告）最近在 11 月 10 日（星期一）发布了其财报。该公司报告本季度每股收益为（14.58 美元），超过了共识预期的（15.56 美元）0.98 美元。研究分析师平均预计 Spruce Biosciences 在当前财政年度将发布-1 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Spruce Biosciences</h2>
<div class="lb-trans"><h2>对 Spruce Biosciences 的对冲基金看法</h2>
</div><p>An institutional investor recently bought a new position in Spruce Biosciences stock. Carlyle Group Inc. purchased a new position in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,896,518 shares of the company's stock, valued at approximately $24,765,000. Spruce Biosciences makes up 0.6% of Carlyle Group Inc.'s portfolio, making the stock its 4th largest position. Carlyle Group Inc. owned about 579.30% of Spruce Biosciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 91.71% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近在 Spruce Biosciences 股票中购买了新头寸。根据该公司在最近向证券交易委员会提交的文件，凯雷集团在第三季度购买了 Spruce Biosciences, Inc.（纳斯达克代码：SPRB - 免费报告）的新头寸。该公司购买了 2,896,518 股该公司的股票，价值约为 24,765,000 美元。Spruce Biosciences 占凯雷集团投资组合的 0.6%，是其第四大头寸。截至最近向证券交易委员会提交的文件，凯雷集团持有 Spruce Biosciences 约 579.30% 的股份。对冲基金和其他机构投资者持有该公司 91.71% 的股票。</p>
</div><h2>Spruce Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Spruce Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.</p>
<div class="lb-trans"><p>Spruce Biosciences, Inc.是一家生物制药公司，专注于开发和商业化稀有内分泌疾病的新疗法。该公司正在开发 tildacerfont，这是一种非类固醇疗法，旨在增强疾病控制并减少患有先天性肾上腺增生（CAH）患者的类固醇负担，目前处于 2b 期临床试验；并评估在经典 CAH 成人患者中减少糖皮质激素的使用，目前也处于 2b 期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Spruce Biosciences</li>
<li>What Are Treasury Bonds?</li>
<li>MongoDB Just Posted a Blowout Quarter—But Is It Too Hot to Touch?</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Spruce Biosciences 更好</li>
<li>什么是国债？</li>
<li>MongoDB 刚刚发布了一个爆炸性的季度——但它是否过热？</li>
<li>什么是成长股及其投资</li>
<li>3 只股票有望受益于谷歌的 AI 突破</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>超越 NVIDIA：5 只半导体股票将主导 2026 年</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSQg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=SPRB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spruce Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Spruce Biosciences 吗？</h2>
</div><p>Before you consider Spruce Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Spruce Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spruce Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Spruce Biosciences 并不在名单上。</p>
</div><p>While Spruce Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spruce Biosciences 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Spruce Biosciences（NASDAQ:SPRB）在 Leerink Partners 被上调至强力买入评级